Communication

News

AGS Therapeutics Strenghtens its Patent Portfolio on Microalgae Extracelluar Vesicles (MEV) with an International Patent Application on Preparation and Uses of MEVs as a Universal Drug Delivery System

9 May 2023
News

AGS Therapeutics Strenghtens its Patent Portfolio on Microalgae Extracelluar Vesicles (MEV) with an International Patent Application on Preparation and Uses of MEVs as a Universal Drug Delivery System

PARIS, FRANCE, May 8, 2023 – AGS Therapeutics, a preclinical stage biotech company pioneering microalgae extracellular vesicles (MEV) as a new delivery system for innovative
therapeutic treatments, announced the recent publication of its International Patent Application WO2023/001894 (PCT/EP2022/070371) entitled Extracellular Vesicles from Microalgae, their Preparation and Uses.

“MEVs can be efficiently loaded with a variety of innovative payloads (including mRNA, siRNA, plasmid-DNA, ASO, peptides, and proteins) and deliver them to various specific tissues and organs, far beyond the liver and lungs” said AGS Chief Operating Officer Lila Drittanti.

The published patent application highlights the versatility of AGS’s breakthrough universal delivery system. As far as versatility, efficiency and ease of exo-loading are concerned, MEVs easily overcome many of the challenges met by current delivery systems based on synthetic lipid nanoparticles (LNPs) and mammalian extracellular vesicles. To know more